Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May;17(5):291-293.
doi: 10.1038/s41581-021-00406-6. Epub 2021 Feb 8.

COVID-19 vaccines and kidney disease

Martin Windpessl #  1   2 , Annette Bruchfeld #  3   4 , Hans-Joachim Anders #  5 , Holly Kramer  6   7 , Meryl Waldman  8 , Laurent Renia  9   10 , Lisa F P Ng  9   10   11   12 , Zhou Xing  13   14   15 , Andreas Kronbichler  16   17
Affiliations

COVID-19 vaccines and kidney disease

Martin Windpessl et al. Nat Rev Nephrol. 2021 May.

Abstract

Patients with kidney diseases should be prioritized for COVID-19 vaccination and the available data suggest that replication-defective viral-vectored vaccines and mRNA vaccines are safe to use. As vaccine responses are likely to be lower in patients with kidney diseases than in the general population, highly potent vaccines should be preferred.

PubMed Disclaimer

Conflict of interest statement

A.B. received grants and personal fees from AstraZeneca and personal fees from ChemoCentryx, Merck/MSD, Vifor and Abbvie, all unrelated to the context of this article. H.J.A. received honoraria from AstraZeneca, GSK, Bayer, Boehringer Ingelheim, Novartis, Previpharma, Inositec and Noxxon, all unrelated to the context of this article. A.K. received honoraria from Miltenyi Biotech, Vifor, TerumoBCT and Novartis, all unrelated to the context of this article.

References

    1. US National Library of Medicine. ClinicalTrials.govhttps://clinicaltrials.gov/ct2/show/NCT04611802 (2021).
    1. Polack FP, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 2020;383:2603–2615. doi: 10.1056/NEJMoa2034577. - DOI - PMC - PubMed
    1. Baden LR, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 2020 doi: 10.1056/NEJMoa2035389. - DOI - PMC - PubMed
    1. Voysey M, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111. doi: 10.1016/S0140-6736(20)32661-1. - DOI - PMC - PubMed
    1. Jeyanathan M, et al. Immunological considerations for COVID-19 vaccine strategies. Nat. Rev. Immunol. 2020;20:615–632. doi: 10.1038/s41577-020-00434-6. - DOI - PMC - PubMed

Publication types

Substances